Abobotulinumtoxina Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 300U, 500U

Reference Brands: Dysport (USA), Azzalure (EU)

Category: Neurology

AbobotulinumtoxinA is a formulation of botulinum toxin type A used to inhibit acetylcholine release at the neuromuscular junction, thereby reducing muscle over-activity / spasticity. It is indicated for adult cervical dystonia (abnormal head posture with neck pain), limb spasticity, glabellar lines (moderate to severe) in adults, and other muscle-related disorders. Because it works via neuromuscular blockade, precise dosing and injection technique are critical; units of this product are not interchangeable with other botulinum toxin products. abobotulinumtoxinA is available in Injection and strengths such as 300U, 500U. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, abobotulinumtoxinA is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

abobotulinumtoxinA can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

AbobotulinumtoxinA is a botulinum toxin type A formulation used for the symptomatic treatment of focal spasticity in adults, particularly affecting the upper limbs. Marketed as Dysport Therapeutic by Ipsen, it is supplied as a sterile injectable in single-use vials of 300 Units and 500 Units. This neurotoxin works by inhibiting the release of acetylcholine at the neuromuscular junction, leading to temporary muscle relaxation and reduction of involuntary muscle contractions.

The dosing of AbobotulinumtoxinA is individualized based on the size, number, and location of the affected muscles. In clinical practice, doses such as 500 Units or 1,000 Units are administered intramuscularly and divided among targeted muscles during a treatment session. The therapeutic effect is temporary, and repeat injections are recommended once the clinical benefit diminishes, typically no sooner than 12 weeks after the previous treatment, with many patients requiring re-treatment between 12 to 16 weeks.

AbobotulinumtoxinA provides an effective and targeted approach for managing upper limb spasticity, improving muscle control, functional ability, and overall quality of life when administered by trained healthcare professionals under controlled clinical settings.